leisure time -WSS

leisure time

author：leisure time 2025-10-01 04:13:13 - browse：28778

In a surprise move, the Food and Drug Administration has called for a meeting of outside advisers to discuss whether an Alzheimer’s drug from Eli Lilly should be approved, even as many outsiders expected the medicine to receive regulatory clearance this month.

The drug, donanemab, succeeded in its Phase 3 trial, resulting in a 35% slowing of Alzheimer’s disease progression versus placebo. But Lilly on Friday said that the FDA expects to call a meeting of an advisory committee to review the trial, saying that the agency had told the company “it wants to further understand topics related to evaluating the safety and efficacy of donanemab, including the safety results in donanemab-treated patients and the efficacy implications of the unique trial design” of the study.

A date for the meeting has not been set yet.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： How generative AI is inspiring dreams of a health data revolution

WSS

Apple Watch's A

AstraZeneca chief proposes a novel edit to the drug pricing bill

Telehealth startups turn to complex chronic diseases

CDC wastewater surveillance dashboard to track bird flu hotspots

House transparency, PBM reform bill gains bipartisan support

Listen: Biogen's potential pivot, & Illumina's next chapter

hotspot

leisure time

Wikipedia

Psychedelics group wrestles with new pharma identity

Brain worms: The science behind RFK Jr.'s parasitic infection

Tori Bowie and the unacceptable rates of Black maternal death

AstraZeneca chief proposes a novel edit to the drug pricing bill

BioMarin wins approval for gene therapy to treat hemophilia A

Making AI in medicine accessible to smaller, and rural hospitals

Cancer drug shortages should be causing more outrage

'Make People Better': The CRISPR babies story you probably don't know

Apple is now the first public company to be valued at $3 trillion

How generative AI is inspiring dreams of a health data revolution

explore

Researchers on aging grapple with how to calculate biological age

Steward Health Care files for bankruptcy

Alcohol isn't healthy after all. Will new dietary guidelines reflect that?

How to fix cancer clinical trials' diversity problem

What nurses really want: sufficient staffing for patient care

Study: AI not yet building 'n

focus

knowledge

focus

hotspot